Hepatitis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers Hepatitis B Treatment Market Trends and the market is segmented by Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Other Types), Drug Class (Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) Inhibitors, Nucleotide Analog Reverse Transcriptase Inhibitors, Nucleotide Analog NS5B Polymerase Inhibitors, Multi Class Combination, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Hepatitis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Hepatitis Therapeutics Market Size

Hepatitis Therapeutics Market Summary
Study Period 2021 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2021 - 2023
CAGR 3.50 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Hepatitis Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Hepatitis Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Hepatitis Therapeutics Market Analysis

The Hepatitis Therapeutics Market is expected to register a CAGR of 3.5% during the forecast period.

The impact of COVID-19 on healthcare services had a substantial impact on the delivery of care and outcomes for patients with chronic diseases. Therefore, there was a decline in the treatment, diagnosis, and follow-up of patients with hepatitis B and C, which had a significant impact on the healthcare industry. Additionally, clinical trials of the drugs were reduced as more and more companies delayed the start of most new courses in several countries. In addition, the COVID-19 epidemic saw a decline in outpatient services for patients with chronic hepatitis, which also had a significant impact on overall market growth. The study published in July 2021 in PubMed stated that the COVID-19 pandemic affected hepatitis prevention, testing, treatment, and vaccination services globally. But the return of elective care procedures around the world is likely to bring the market's growth back to where it was before the pandemic.

The market is anticipated to witness rapid growth due to the growing incidence of hepatitis, growing government support for awareness of hepatitis diseases, and increased availability of highly technologically advanced medical products. Hepatitis is an inflammation of the liver. Hepatitis may be due to drugs, alcohol consumption, or other medical conditions affecting the liver. But in most cases, it is caused by a virus called viral hepatitis, and the most common types are hepatitis A, B, and C. Hepatitis B is very common and can lead to severe cirrhosis of the liver, which can be fatal. Moreover, government initiatives to increase awareness regarding hepatitis and its treatment are anticipated to boost market growth over the forecast period. For instance, in June 2022, the "World Hepatitis Summit (WHS)" occurred as a virtual event. The World Hepatitis Summit 2022 was co-sponsored by the World Health Organization (WHO). The summit provides a platform for a broad hepatitis community to take stock of progress to date and share ideas, experiences, and best practises in addressing the many challenges of viral hepatitis.

Furthermore, according to the Hepatitis B Foundation 2022 update, two billion people have been infected with the hepatitis B virus (one out of three people). Approximately 1.5 million people become newly infected each year. Almost 300 million people are chronically infected. Thus, the increasing burden of hepatitis is propelling the growth of the market. Additionally, in March 2021, Dicerna Pharmaceuticals and Roche commenced the Phase II combination trial of the investigational GalXC RNAi candidate, RG6346, for the treatment of chronic hepatitis B virus (HBV) infection. In addition, in March 2022, VBI Vaccines Inc. received FDA approval for the 3-antigen HBV vaccine for adults in the United States, PreHevbrio for hepatitis B. Therefore, such research and development activities in the market are expected to drive market growth.

Therefore, the increase in the prevalence of the hepatitis B virus, the promising pipeline for hepatitis drugs, and government-sponsored programmes to encourage patients to accept hepatitis drugs are likely to drive the hepatitis therapeutics market over the forecast period. During the analysis period, the market is likely to grow slowly because of strict regulations and bad reimbursement policies.

Hepatitis Therapeutics Industry Overview

The hepatitis therapeutics market is competitive and consists of several major players. However, in terms of market share, only a few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc., Gilead Sciences, Inc., AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited, and Cipla Inc.

Hepatitis Therapeutics Market Leaders

  1. AbbVie Inc.

  2. Bristol Myers Squibb Company

  3. F Hoffmann-La Roche Ltd

  4. Gilead Sciences Inc.

  5. Merck KGaA

  6. *Disclaimer: Major Players sorted in no particular order
hepatitis.png
Need More Details on Market Players and Competiters?
Download PDF

Hepatitis Therapeutics Market News

  • November 2022: Gilead Sciences, Inc. received U.S. Food and Drug Administration (FDA) approval for the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older with compensated liver disease.
  • April 2022: Lupin received approval from the United States Food and Drug Administration for tenofovir alafenamide tablets to treat chronic hepatitis B virus infection.

Hepatitis Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Viral Hepatitis
    • 4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
    • 4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Issues
    • 4.3.2 Poor Reimbursement Policies
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Disease Type
    • 5.1.1 Hepatitis A
    • 5.1.2 Hepatitis B
    • 5.1.3 Hepatitis C
    • 5.1.4 Hepatitis D
    • 5.1.5 Other Types
  • 5.2 By Drug Class
    • 5.2.1 Interferon
    • 5.2.2 Monoclonal Antibody
    • 5.2.3 Non-structural protein 5A (NS5A) Inhibitors
    • 5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
    • 5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
    • 5.2.6 Multi Class Combination
    • 5.2.7 Other Drug Classes
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck KGaA
    • 6.1.2 Gilead Sciences Inc.
    • 6.1.3 AbbVie Inc.
    • 6.1.4 Bristol Myers Squibb Company
    • 6.1.5 F Hoffmann-La Roche, Ltd
    • 6.1.6 LAURUS Labs
    • 6.1.7 Zydus Cadila
    • 6.1.8 Hetero Healthcare Limited
    • 6.1.9 NATCO Pharma Limited
    • 6.1.10 Cipla Inc.
    • 6.1.11 Johnson & Johnson
    • 6.1.12 Biocon
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Hepatitis Therapeutics Industry Segmentation

As per the scope of the report, hepatitis is an inflammation of the liver. The standard treatment for treating hepatitis includes several antiviral medications for different types of hepatitis, namely A, B, and C. The most effective therapy for combating the condition is a combination of different drugs. The Hepatitis Therapeutics Market is classified into Disease Type (Hepatitis A, B, C, D, and Others), Drug Class (Interferon, Monoclonal Antibody, Non-structural Protein 5A (NS5A) Inhibitors, Nucleotide Analog Reverse Transcriptase Inhibitors, Nucleotide Analog NS5B Polymerase Inhibitors, Multi-Class Combination, and Others), and Geography (North America, Europe, The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Disease Type Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Other Types
By Drug Class Interferon
Monoclonal Antibody
Non-structural protein 5A (NS5A) Inhibitors
Nucleotide Analog Reverse Transcriptase Inhibitors
Nucleotide Analog NS5B Polymerase Inhibitors
Multi Class Combination
Other Drug Classes
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Hepatitis Therapeutics Market Research FAQs

What is the current Hepatitis Therapeutics Market size?

The Hepatitis Therapeutics Market is projected to register a CAGR of 3.5% during the forecast period (2025-2030)

Who are the key players in Hepatitis Therapeutics Market?

AbbVie Inc., Bristol Myers Squibb Company, F Hoffmann-La Roche Ltd, Gilead Sciences Inc. and Merck KGaA are the major companies operating in the Hepatitis Therapeutics Market.

Which is the fastest growing region in Hepatitis Therapeutics Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Hepatitis Therapeutics Market?

In 2025, the North America accounts for the largest market share in Hepatitis Therapeutics Market.

What years does this Hepatitis Therapeutics Market cover?

The report covers the Hepatitis Therapeutics Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Hepatitis Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Hepatitis B Treatment Industry Report

Statistics for the 2025 Hepatitis Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hepatitis Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.